昌吉妇科打胎的价格昌吉女子专科医院,昌吉月经量多是怎么引起的,昌吉如果包皮不割会怎样,昌吉流产一般多少钱,昌吉专业阴道紧缩修补的医院,昌吉看男科哪家医院更好,昌吉包皮手术40天

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

BEIJING, Jan. 22 (Xinhua) -- Beijing is ready to kick off its first ever car license plates lottery, to be broadcast live both on TV and over the Internet on Jan. 26, said officials with the allotment office Saturday.A total of 17,600 car license plates will be allocated to qualified individual applicants through the lottery, in keeping with the principles of openness, fairness and equity, according to the office.Validation for the first batch of 210,178 individual applicants has been completed, and the office will make public the results, as well as lottery time and rules, on Tuesday.Applicants can check out the validation information at bjhjyd.gov.cn.The first group of car license plates for institution and company applicants will also be allocated through the lottery on the same day.The Beijing municipal government put in place the lottery mechanism at the end of last year in an effort to curb the capital city's fast growth of automobiles, which resulted in worsening traffic jams.The new mechanism seeks to reduce new car registrations by allowing only 240,000 in 2011, or about one-third of new cars registered in 2010.Data from the Beijing Municipal Commission of Transport (BMCT) shows there were only 78,000 cars in Beijing in 1978 and 200,000 in 1985.However, the number of cars soared after the country entered the 21st century amid fast economic growth and urbanization.Within 13 years, the number of cars in Beijing more than quadrupled to 4.76 million in 2010 from 1 million in 1997, according to the BMCT.

SYDNEY, May 24 (Xinhua) -- Australian soldiers and contractors in Iraq might have been exposed to blood-borne diseases such as HIV or hepatitis, as staff at Defense's main hospital unit in the Middle East failed to sterilize surgical equipment properly, local media reported on Tuesday.Fairfax newspapers reported the safety breach occurred at the AL Minhad Air Base in the United Arab Emirates over a 19 month period, from February 2009 to August 2010, but soldiers were alerted to the problem only a week ago.A Defense Department memo to troops has warned that soldiers and contractors who passed through the air base hospital near Dubai should ensure they had their blood screened, The Sydney Morning Herald reported."Personnel who underwent a surgical procedure during that period are possibly at risk of acquiring a blood-borne disease," the memo said.However, the health alert says the risk to Australian Defense Force personnel is low, as blood-borne diseases within the force are rare and personnel are vaccinated against hepatitis.The Defense Force's Surgeon-General, Major General Paul Alexander, wrote the "internal procedural issue" was dealt with by the health system and measures were put in place to prevent a repeat of the error.

SYDNEY, Jan. 25 (Xinhua) -- Huawei Technologies, on Monday asked a U.S. District Court to prevent Motorola from illegally transferring Huawei's intellectual property (IP) to Nokia Siemens Networks ("NSN"), officials of Huawei told Xinhua in Sydney, Australia on Tuesday.As a leading player in providing next generation telecommunications network solutions, Huawei took this action as NSN seeks to complete its 1.2 billion U.S. dollars acquisition of Motorola's wireless network business.Since 2000, Huawei and Motorola have had a cooperative relationship in the radio access network and core network businesses, where Motorola has resold Huawei wireless network products to customers under the Motorola name. During this period, Motorola was provided with products and confidential Huawei IP developed by Huawei's team of more than 10,000 engineers.Since the July 2010 announcement by NSN of its purchase of Motorola's wireless network business, Huawei has tried to ensure that Motorola does not transfer this confidential information to NSN.According to officials of Huawei, Motorola's failure to adopt measures sufficient to ensure that Huawei's proprietary information remains confidential has compelled the company to file for the appropriate legal protection of its rights.The officials said Huawei respects the rights of intellectual property holders and is equally committed to the protection of its own innovations and intellectual property.Nearly half of Huawei's 100,000 plus employees are engaged in research and development and Huawei allocates an average of 10 percent of all revenues to R&D annually. By the end of 2010, Huawei had applied for 49,040 essential patents on a global basis.

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.